Tolvaptan treatment in hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): effects on survival in patients with cancer

[1]  T. Ikeda,et al.  The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients , 2018, Heart and Vessels.

[2]  R. Gralla,et al.  Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT‐1 and SALT‐2 trials , 2017, Cancer medicine.

[3]  M. Pistelli,et al.  Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy , 2016, Oncotarget.

[4]  D. Lubeck,et al.  Treatment Length of Stay for Chronic Heart Failure Patients in a Hyponatremia Registry Patients in a Hyponatremia Registry , 2016 .

[5]  J. Castillo,et al.  The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients , 2016, BMC Cancer.

[6]  R. Berardi,et al.  Hyponatremia in cancer patients: Time for a new approach. , 2016, Critical reviews in oncology/hematology.

[7]  J. Verbalis,et al.  Hyponatremia Improvement Is Associated with a Reduced Risk of Mortality: Evidence from a Meta-Analysis , 2015, PloS one.

[8]  R. Sahay,et al.  Hyponatremia: A practical approach , 2014, Indian journal of endocrinology and metabolism.

[9]  Amit Lahoti,et al.  Tolvaptan in hospitalized cancer patients with hyponatremia: A double‐blind, randomized, placebo‐controlled clinical trial on efficacy and safety , 2014, Cancer.

[10]  J. Castillo,et al.  Diagnosis and management of hyponatremia in cancer patients. , 2012, The oncologist.

[11]  C. Grohé,et al.  Ist die Hyponatriämie (HN) ein Prognosefaktor für das Gesamtüberleben der Patienten mit Lungenkarzinom? , 2011, Pneumologie.

[12]  O. Hansen,et al.  The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period. , 2010, Lung cancer.

[13]  T. Berl,et al.  Oral tolvaptan is safe and effective in chronic hyponatremia. , 2010, Journal of the American Society of Nephrology : JASN.

[14]  K. Schulman,et al.  Medical costs of abnormal serum sodium levels. , 2008, Journal of the American Society of Nephrology : JASN.

[15]  T. Berl,et al.  Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. , 2006, The New England journal of medicine.

[16]  David Wile,et al.  Characteristics and mortality of severe hyponatraemia – a hospital‐based study , 2006, Clinical endocrinology.

[17]  Y. Katayama,et al.  Cerebral salt wasting in subarachnoid hemorrhage rats: model, mechanism, and tool. , 2005, Life sciences.

[18]  B. Palmer.  Hyponatremia in patients with central nervous system disease: SIADH versus CSW , 2003, Trends in Endocrinology & Metabolism.

[19]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[20]  M. Rosner,et al.  Electrolyte disorders associated with cancer. , 2014, Advances in chronic kidney disease.

[21]  D. Annane,et al.  Special feature Clinical Practice Guideline on Diagnosis and Treatment of Hyponatraemia , 2015 .